Effects of lamotrigine on behavioral and cardiovascular responses to cocaine in human subjects

American Journal of Drug and Alcohol Abuse

Volumn 26, Issue 1, 2000, Pages 47-59

  Winther, Lynn C ^a,b,c,e   Saleem, Rehan ^b,c   McCance Katz, Elinore F ^a,c,d   Rosen, Marc I ^a,c,d   Hameedi, Faiq A ^a,b,c   Pearsall, H Rowland ^b,c   Jatlow, Peter I ^a   Kosten, Thomas R ^a,c,d   Woods, Scott W ^b,c  

^a Substance Abuse Center   (United States)

^b Yale University School of Medicine   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LAMOTRIGINE; PLACEBO;

ADULT; ARTICLE; BEHAVIOR; BLOOD PRESSURE; BLOOD SAMPLING; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RESPONSE; CLINICAL ARTICLE; CLINICAL TRIAL; COCAINE DEPENDENCE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HEART RATE; HUMAN; HUMAN EXPERIMENT; MALE; MOOD; NORMAL HUMAN; PATIENT SATISFACTION; QUESTIONNAIRE; RATING SCALE; VOLUNTEER;

ADMINISTRATION, ORAL; ADULT; AFFECT; AROUSAL; BLOOD PRESSURE; COCAINE-RELATED DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HEART RATE; HUMANS; MALE; PREMEDICATION; TRIAZINES;

EID: 0034089280     PISSN: 00952990     EISSN: None     Source Type: Journal    
DOI: 10.1081/ADA-100100590     Document Type: Article

References (43)

1. National Institute on Drug Abuse, Facts About Cocaine Abuse and Treatment, NIDA Notes 10(5), Author, Rockville, Maryland, 1995.
2. Covi, L., Montoya, I. D., Hess, J. M., et al., Desipramine for treatment of cocaine dependence: randomized, double-blind, placebo-controlled study, ACNP Ann. Meeting Abs. 173 (1993).
3. Covi, L., Hess, J. M., Kreiter, N. A., et al., Desipramine and counselling for treatment of cocaine dependence: a controlled study, NIDA Res. Monogr. 153:309 (1994).
4. Walsh, S. L., Preston, K. L., Sullivan, J. T., et al., Fluoxetine alters the effects of intravenous cocaine in humans, J. Clin. Psychopharmacol. 14:396-407 (1994).
5. Walsh, S. L., Sullivan, J. T., and Bigelow, G. E., Fluoxetine effects on cocaine responses: a double-blind assessment, NIDA Res. Monogr. 153:310 (1994).
6. Batki, S. L., Washburn, A. M., Delucchi, K., et al., A controlled trial of fluoxetine in crack cocaine dependence, Drug Alcohol Depend. 41:137-142 (1996).
7. Preston, K. L., Sullivan, J. T., Strain, E. C., et al., Effects of cocaine alone and in combination with bromocriptine in human cocaine abusers, J. Pharmacol. Exp. Ther. 262:279-291 (1992).
8. Weddington, W. W., Brown, B. S., Haertzen, C. A., et al., Comparison of amantadine and desipramine combined with psychotherapy for treatment of cocaine dependence, NIDA Res. Monogr. 95:483-484 (1989).
9. Alterman, A. I., Droba, M., Antelo, R. E., et al., Amantadine may facilitate detoxification of cocaine addicts, Drug Alcohol Depend. 31:19-29 (1992).
10. Margolin, A., Kosten, T. R., Avants, S. K., et al., A multicenter trial of bupropion for cocaine dependence in methadone-maintained patients, Drug Alcohol Depend. 40:125-131 (1995).
11. Sherer, M. A., Kumor, K. M., and Jaffe, J. H., Effects of intravenous cocaine are partially attenuated by haloperidol, Psychiatry Res. 27:117-125 (1989).
12. Stine, S., Krystal, J., Kosten, T., et al., Mazindol treatment of cocaine abusers, ACNP Ann. Meeting Abs. 228 (1992).
13. Preston, K. L., Sullivan, J. T., Berger, P., et al., Effects of cocaine alone and in combination with mazindol in human cocaine abusers, J. Pharmacol. Exp. Ther. 267:296-307 (1993).
14. Hatsukami, D., Keenan, R., Halikas, J., et al., Effects of carbamazepine on acute responses to smoked cocaine-base in human cocaine users, Psychopharmacology 104:120-124 (1991).
15. Halikas, J. A., Crosby, R. D., Pearson, V. L., et al., A randomized double-blind study of carbamazepine in the treatment of cocaine abuse, Clin. Pharmacol. Ther. 62:89-105 (1997).
16. Montoya, I. D., Levin, F. R., Fudala, P. J., et al., Double-blind study with carbamazepine for treatment of cocaine dependence, ACNP Ann. Meeting Abs. 173 (1993).
17. Kranzler, H. R., Bauer, L. O., Hersh, D., et al., Carbamazepine treatment of cocaine dependence: a placebo-controlled trial [see comments], Drug Alcohol Depend. 38:203-311 (1995).
18. Kosten, T., Silverman, D. G., Fleming, J., et al., Intravenous cocaine challenges during naltrexone maintenance: a preliminary study, Biol. Psychiatry 32:543-548 (1992).
19. Carroll, K., Ziedonis, D., O'Malley, S., et al., Pharmacologic interventions for abusers of alcohol and cocaine: disulfiram versus naltrexone, Am. J. Addict. 2:77-79 (1993).
20. Hameedi, F. A., Rosen, M. I., McCance-Katz, E. F., et al., Behavioral, physiological, and pharmacological interaction of cocaine and disultiram in humans, Biol. Psychiatry 37:560-563 (1995).
21. Pulvirenti, L., Sung, R., and Koob, G. F., Microinjection of NMDA but not quisqualate receptor antagonists into the nucleus accumbens modulates intravenous cocaine self-administration in rats, Soc. Neurosci. Abs. 15:1098 (1989).
22. Pulvirenti, L., Swerdlow, N. R., and Koob, G. F., Nucleus accumbens NMDA antagonist decreases locomotor activity produced by cocaine, heroin or accumbens dopamine, but not caffeine, Pharmacol. Biochem. Behav. 40:841-845 (1991).
23. Johnson, M., Bush, L. G., Gibb, J. W., et al., Role of N-methyl-D-aspartate (NMDA) receptors in the response of extrapyramidal neurotensin and dynorphin A systems to cocaine and GBR 12909, Biochem. Pharmacol. 41:649-652 (1991).
24. Torres, G., and Rivier, C., Cocaine-induced expression of striatal c-fos in the rat is inhibited by NMDA receptor antagonists, Brain Res. Bull. 30:173-176 (1993).
25. Rockhold, R. W., Oden, G., Ho, I. K., et al., Glutamate receptor antagonists block cocaine-induced convulsions and death, Brain Res. Bull. 27:721-723 (1991).
26. Witkin, J. M., and Tortella, F. C., Modulators of N-methyl-D-aspartate protect against diazepam-or phenobarbital-resistant cocaine convulsions, Life Sci. 48:L51-L56 (1991).
27. Moghaddam, B., and Bolinao, M. L., Glutamatergic antagonists attenuate ability of dopamine uptake blockers to increase extracellular levels of dopamine: implications for tonic influence of glutamate on dopamine release, Synapse 18:337-342 (1994).
28. Pap, A., and Bradberry, C. W., Excitatory amino acid antagonists attenuate the effects of cocaine on extracellular dopamine in the nucleus accumbens, J. Pharmacol. Exp. Ther. 274:127-133 (1995).
29. Leach, M. J., Marden, C. M., and Miller, A. A., Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action, Epilepsia 27: 490-497 (1986).
30. McGeer, E. G., and Zhu, S. G., Lamotrigine protects against kainate but not ibotenate lesions in rat striatum, Neurosci. Lett. 112:348-351 (1990).
31. Margolin, A., Avants, S. K., DePhillips, D., et al., A preliminary investigation of lamotrigine for cocaine abuse in HIV-seropositive patients, Am. J. Drug Alcohol Abuse 24:85-101 (1998).
32. Cohen, A. F., Ashby, L., Crowley, D., et al., Lamotrigine (BW430C), a potential anticonvulsant. Effects on the central nervous system in comparison with phenytoin and diazepam, Br. J. Clin. Pharmacol. 20:619-629 (1985).
33. Van Dyke, C., Ungerer, J., Jatlow, P., et al., Intranasal cocaine: dose relationships of psychological effects and plasma levels, Int. J. Psychiatry Med. 12:1-13 (1982).
34. Fischman, M. W., and Schuster, C. R., Cocaine effects in sleep-deprived humans, Psychopharmacology 72:1-8 (1980).
35. McNair, D. M., Lorr, M., and Droppleman, L. F., Profile of Mood States (Manual), Educational and Industrial Testing Service, San Diego, California, 1971.
36. Stevens, J., Applied Multivariate Statistics for the Social Sciences, 2nd ed., Lawrence Erlbaum Associates, Hillsdale, New Jersey, 1992, p. 448.
37. Smith, D., Baker, G., Davies, G., et al., Outcomes of add-on treatment with lamotrigine in partial epilepsy, Epilepsia 34:312-322 (1993).
38. Smith, D., Chadwick, D., Baker, G., et al., Seizure severity and the quality of life, Epilepsia 34:S31-S35 (1993).
39. Waldmeier, P. C., Baumann, P. A., Wicki, P., et al., Similar potency of carbamazepine, oxcarbazepine, and lamotrigine in inhibiting the release of glutamate and other neurotransmitters. Neurology 45:1907-1913 (1995).
40. Rosen, M. I., Pearsall, H. R., and Kosten, T. R., The effect of lamotrigine on naloxone-precipitated opiate withdrawal, Drug Alcohol Depend. 52:173-176 (1998).
41. Cone, E. J., Pharmacokinetics and pharmacodynamics of cocaine, J. Anal. Toxicol. 19:459-478 (1995).
42. Shuaib, A., Mahmood, R. H., Wishart, T., et al., Neuroprotective effects of lamotrigine in global ischemia in gerbils. A histological, in vivo microdialysis and behavioral study, Brain Res. 702: 199-206 (1995).
43. Crumrine, C., Bergstrand, K., Cooper, A. T., et al., Lamotrigine prevents brain damage resulting from global ischemia caused by cardiac arrest with resuscitation, Soc. Neurosci. Abs. 23:2433 (1997).